To investigate the relationship between the fetal hemoglobincontaining erythroblasts (F blasts) and apoptosis in myelodysplastic syndromes (MDS), we immunohistochemically assessed F blasts, F cells, and apoptosis in 137 patients with MDS. A marked increase in the number of F blasts in the bone marrow was identified in 116 of 137 patients (84.7%), and the number of F cells was elevated in 54 patients (39.4%). Among the erythroblasts stained by anti-glycophorin C antibody, the mean percentage of F blasts was 14.63 ؎ 9.17% in MDS, which was significantly higher than that in non-MDS patients with stress erythropoiesis (4.82 ؎ 3.35%, P Ͻ 0.01), although there were no significant differences in the number of F cells between these groups. In particular, 62 of the 137 MDS patients (45.3%) had an apparent increase in F blasts but no elevation of F cells. The apoptotic rate was significantly higher in the patients with a F blast/F cell (Fb/Fc) ratio у5.0 than in those with a Fb/Fc ratio Ͻ1.0 (P Ͻ 0.01). The results indicate that F cell precursors are incapable of maturing into functioning endstage F cells, presumably owing to apoptotic cell death. The measurement of F blasts in the bone marrow is needed for the precise evaluation of fetal-type erythropoiesis in MDS.
Introduction
Fetal hemoglobin (HbF) is produced mainly in fetal life and rapidly declines to extremely low levels by the age of 1 year. 1 In normal adults, HbF production is minimal and HbF is restricted to a specific population referred to as F cells. 2 However, the reemergence of HbF production may occur in certain inherited and acquired conditions in adulthood, such as myelodysplastic syndromes (MDS) and hemoglobinopathies. 3 Erythropoietic stress as seen in acute blood loss, chemotherapeutic marrow ablation, malignancies affecting the erythropoietic system, and acute hemolysis is also associated with increased F cell production. [4] [5] [6] Increased F cells in MDS have been reported to be of prognostic significance. 7 The HbF concentration has been assessed by alkali denaturation, electrophoresis, or high performance liquid chromatography, [8] [9] [10] whereas F cells have been measured by an acid elution technique, an indirect immunofluorescence method on slides, or flow cytometry. [11] [12] [13] However, such methods do not provide any information about HbF expression or the distribution of F cell precursors in the bone marrow. Recently, we reported a method to detect HbF-containing erythroblasts in the bone marrow by immunohistochemistry using a new anti-HbF antibody against a synthetic peptide antigen, and defined HbF-containing erythroblasts or F cell precursors as F blasts. 14 poietic organs, and the HbF concentration is also based on the concentrations of F cell hemolysates. Consequently, the measurement of F cell precursors in the bone marrow might provide more accurate information on fetal-type erythropoiesis in adults. In contrast to the flow cytometric F cell assay, immunohistochemistry for F blasts preserves the morphologic characteristics of the HbF-containing erythroid precursors in relation to the histologic features and allows detailed study of HbF production not only in adult bone marrows, but also in fetal erythropoietic organs. An apparent paradox in MDS is that patients with this disease show peripheral cytopenia despite normal or high cellularity in their bone marrows. 15 Cytopenia in MDS is considered to be the result of pronounced hematopoietic insufficiency, and this ineffective hematopoiesis is contributed to the increased apoptosis of bone marrow precursors. 16 Several investigators have reported a higher incidence of F cells in patients with MDS compared with controls. 7, 17 However, all the studies on fetal-type erythropoiesis in MDS have thus far been based mainly on the measurement of HbF concentrations or the percentage of F cells in the peripheral blood. Furthermore, there have been no studies which have closely examined the incidence of F blasts in the bone marrow of MDS patients and the significance of the F blast/F cell (Fb/Fc) ratio. Hence, in this study we assessed the F blasts in the bone marrow from patients with MDS, and investigated the relationship between the Fb/Fc ratio and apoptosis.
Subjects and methods

Patients selection
A total of 137 patients with MDS were selected from the bone marrow case files of the Department of Pathology, Nagoya University Hospital. The MDS patients included 36 with refractory anemia (RA), 15 RA with ringed sideroblasts (RARS), 31 RA with excess of blasts (RAEB), 43 RA with excess of blasts in transformation (RAEB-t), and 12 with chronic myelomonocytic leukemia (CMMoL). The study group comprised 75 men and 62 women with a mean age of 67 years (range 36 to 89 years). We studied 14 healthy individuals as controls, who had no abnormalities in the bone marrow or peripheral blood. As additional controls, we also assessed the F blasts in the bone marrow from non-MDS patients (n ϭ 25) with stress erythropoiesis, such as acute hemolytic anemia (n ϭ 7) and carcinoma (n ϭ 10) or lymphoma (n ϭ 8) involving the bone marrow. The mean ages of the two control groups were 61 years (31 to 78 years) and 56 years (37 to 81 years), respectively.
Immunohistochemical staining
Serial sections (3 m) were immunohistochemically stained for HbF, single-stranded DNA (ssDNA), glycophorin C (GPC), and p53. To detect the F blasts and F cells in the bone marrow clot sections, we used a polyclonal anti-HbF antibody that we recently developed using a synthetic peptide as an immunogen.
14 The assay for apoptosis was an immunohistochemical method based on the binding of a polyclonal antibody to ssDNA, as described previously. 18 Antibodies against ssDNA, GPC, and p53 were purchased from Dako (Glostrup, Denmark). Paraffin-embedded bone marrow clot sections were processed using a streptavidin-biotin complex method or an immunoperoxidase technique. Before applying the HbF antibody, slides were treated with 0.1% trypsin in 0.05 M Tris buffer (pH 7.6) at 37°C for 30 min. Known positive controls (a 29-week-old fetal liver for HbF, a Burkitt's lymphoma for ssDNA, and a colorectal carcinoma for p53) as well as negative controls (sections in which the primary antibody was replaced by non-immune mouse or rabbit serum) were also stained in each run.
The proportion of F blasts was defined as the HbF synthetic rate, which represented the percentage of F blasts identified by the anti-HbF antibody among 1000 erythroblasts stained by the anti-GPC antibody. HbF-containing erythrocytes (F cells) were counted with a light microscope (magnification ϫ400) in well-dispersed areas of the bone marrow clot sections, and were expressed as a percentage of the total number of 10 4 erythrocytes. The apoptotic rate and the number of cells positive for p53 were expressed as a percentage of immunoreactive nuclei out of 1000 bone marrow cells. All slides were reviewed by two different investigators, who were blinded to clinical data.
Statistical tests
The nonparametric Mann-Whitney U test was used for the comparison of mean values between two parameters. Correlations between the number of F blasts and p53 expression were assessed by the Pearson correlation coefficient. Data analysis was performed using an SAS statistical program (SAS Institute, Cary, NC, USA). P Ͻ 0.01 was considered statistically significant.
Results
F blasts and F cells in bone marrow from patients with MDS
The proportions of F blasts and F cells in the bone marrow from 137 patients with MDS are summarized in Table 1 . Among the erythroblasts stained by anti-GPC antibody, the percentage of F blasts was 14.63 Ϯ 9.17% in MDS, which was significantly higher than that in the non-MDS patients with stress erythropoiesis (4.82 Ϯ 3.35%, P Ͻ 0.01). However, there was no significant difference in the percentage of F cells between the MDS patients and the non-MDS patients with stress erythropoiesis. Among the 137 patients, 116 (84.7%) had a percentage of F blasts in the bone marrow that exceeded 0.3%, which was taken as the provisional cutoff value based on the mean Ϯ 2s.d. for the control group. The percentage of F cells was greater than 0.7% in 39.4% (54/137) of patients, Percentages of F blasts in the bone marrow from patients with MDS were significantly higher than for the controls and for the non-MDS patients with stress erythropoiesis (P Ͻ 0.01, respectively). b There were no significant differences in the F cell levels between the MDS and the non-MDS patients.
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the cutoff value also based on the mean Ϯ 2 s.d. for the controls.
To further investigate the association between the increased F blast proportions and F cell levels, the 137 MDS patients were subdivided into three groups according to the percentage of F blasts and F cells in the bone marrow (Table 2 ). An increase in both F blasts (Ͼ0.3%) and F cells (Ͼ0.7%) was observed in 39.4% (54/137) of MDS patients and in 76.0% (19/25) of non-MDS patients with stress erythropoiesis (P Ͻ 0.01). It is noteworthy that patients who had an increased F blast percentage (Ͼ0.3%) but no increase in the percentage of F cells (Ͻ0.7%) were identified in 45.3% (62/137) of the MDS patients; however, there were no such cases in the non-MDS patients with stress erythropoiesis.
F blast/F cell (Fb/Fc) ratio and apoptotic rate
The F blast percentage in each subtype of MDS, along with the corresponding F cells and Fb/Fc ratio are listed in Table  3 . There were no significant differences in the mean proportions of F blasts or F cells among the subtypes of MDS, although advanced MDS, especially RAEB or RAEB-t, showed a trend toward an increased percentage of F blasts in the bone marrow. Among the subtypes of MDS, the Fb/Fc ratio was the highest in RAEB and was significantly above the values in RA or RARS (P Ͻ 0.01, in each group).
The expression of ssDNA and p53 was elevated in 42 patients (30.6%) and in 101 patients (73.7%) by greater than 1.0%, respectively, which was the cutoff value taken from the mean Ϯ 2s.d. for controls. The apoptotic rate averaged 5.4% in the MDS patients, which was significantly above the values in the control subjects (0.5%, P Ͻ 0.01). RAEB and RAEB-t showed relatively high apoptotic rates compared with RA, RARS, and CMMoL. No significant correlations between the F blast percentages and p53 expression were noted. As shown in Table 4 , it is apparent that ssDNA expression was significantly higher in the patients with an Fb/Fc ratio у5.0 than in those with an Fb/Fc ratio Ͻ1.0 (P Ͻ 0.01); however, no significant difference in p53 expression was observed between the two groups. Fb/Fc ratio, F blast/F cell ratio. Data are expressed as the mean Ϯ sd. a Apoptotic rate in controls: 0.5 Ϯ 0.2%; b p53 expression in controls: 0.4 Ϯ 0.3%. There were no significant differences in the mean values of F blasts, F cells, or p53 among the MDS subtypes; however, the Fb/Fc ratio was significantly higher in RAEB than in RA or RARS (P Ͻ 0.01, respectively). Among the subtypes of MDS, RAEB and RAEB-t showed a relatively high apoptotic rate compared to RA, RARS and CMMoL. 
Distribution of F blasts in bone marrow
Several distinct patterns of HbF expression in erythroid precursors were observed in patients with MDS. In all the controls who had F blasts in their bone marrow or in 63.2% of the non-MDS patients, F blasts were mostly dispersed in a widespread area without forming any clusters of cells. Clusters of F blasts (small cell colonies with more than three F blasts) were seen in patients with MDS (56.0%) and in non-MDS patients with stress erythropoiesis (36.8%). However, sheets of F blasts were observed only in patients with MDS (31.9%), which were characterized by a confluence of cells with more than 50 F blasts (Table 5 and Figure 1 ). HbF expression was largely restricted to immature erythroid precursors or dysplastic erythroblasts.
Discussion
This study evaluated the percentage of F blasts and HbF production in the bone marrow from patients with MDS and an association between the Fb/Fc ratio and apoptosis. We found a significant increase in F blasts in the bone marrow from patients with MDS compared to non-MDS patients with stress erythropoiesis or healthy controls. In particular, nearly half of the MDS patients, who had markedly increased proportions of F blasts, had normal levels of F cells. We also discovered an increase of apoptosis predominantly in MDS patients with an elevated Fb/Fc ratio. Similar data on HbF expression in erythrocytes were reported previously by other investigators, who found elevated HbF concentrations in up to 50% of MDS patients tested. 9, 19, 20 Craig et al 21 found that the mean F cell percentage in MDS patients was not statistically different from that in normal blood donors. In contrast, in the present study, HbF-containing erythrocytes in the bone marrow were seven times as abundant in patients with MDS as in healthy controls. Measurement of the HbF concentration or the F cell assay may have differed between the two studies. In this study, we used a polyclonal anti-HbF antibody, which we developed to confirm its characterization with high specificity and sensitivity to fetal hemoglobin. 14 Reactivation of HbF production in patients with MDS is a common phenomenon and an elevated F cell count has been reported to be a possible prognostic factor for MDS. 7, 17, 21 The present study is the first documentation that F blasts are found frequently in most patients with MDS. We investigated the F blast levels in MDS patients and non-MDS patients with stress erythropoiesis. The mean percentage of F blasts was three times higher in the MDS patients than in the non-MDS patients; however, there were no significant differences in the F cell levels between the two groups. Furthermore, patients who had elevated F blasts but no increase in F cell levels were identified in approximately half of the MDS patients, whereas there were no such subjects in the non-MDS patients with stress erythropoiesis. These results suggest that F cell precursors are incapable of maturing effectively to the level of circulating F cells in MDS.
Leukemia MDS are bone marrow stem cell disorders characterized by ineffective hematopoiesis leading to blood cytopenias despite the presence of a cellular marrow, and a propensity towards leukemic transformation. 22 Increased apoptosis in MDS has been proposed as a possible explanation for the ineffective hematopoiesis. [23] [24] [25] [26] To investigate why enhanced F blast production is not accompanied by an elevation of F cells in some patients with MDS, we examined the relationship between the Fb/Fc ratio and apoptosis. There were no significant differences in the apoptotic rate between the subjects with an Fb/Fc ratio Ͻ1.0 and those with Fb/Fc ratio у1.0. However, the mean values of the apoptotic rate showed significant differences when we compared the subjects with an Fb/Fc ratio у5.0 and those with an Fb/Fc ratio Ͻ1.0: the apoptotic rate was three-fold higher in the subjects with an Fb/Fc ratio у5.0 than in the subjects with an Fb/Fc Ͻ1.0. Interestingly, an increase in the Fb/Fc ratio was prominent in the RAEB and RAEB-t subtypes, which showed a relatively high apoptotic rate. These results indicate that only the patients with moderately increased Fb/Fc ratio are relevant to apoptosis. Our data also suggest that the normal percentage of F cells in the patients with enhanced F blast production is at least partly due to apoptotic cell death in MDS. In this respect, the F cell assay does not seem to reflect sufficiently the extent of fetaltype erythropoiesis in MDS. We therefore believe that F blasts should be measured to investigate HbF production in MDS.
Our results for the apoptotic rate in MDS were in general agreement with the previous report of Shimazaki et al 27 who found that the apoptotic rate was higher in the MDS patients than in the control subjects and was predominant in the erythroblasts. Several studies have confirmed a higher apoptotic rate in the bone marrow of MDS patients compared with controls, but these incidences varied widely between authors. Raza et al 28 using an in situ end-labelling (ISEL) technique to identify fragmented DNA ends generated during apoptosis, demonstrated that more than 50% of MDS patients had excessive trilineage intramedullary cell death. In contrast, Lepelley et al 29 reported that a moderate increase in the percentage of apoptotic cells (2.5 to 5%) was observed in 15% of cases, and was predominant in erythroblasts. In this study, using an immunohistochemical ssDNA assay, which is sensitive and specific to early stages of apoptosis, we observed significantly increased apoptosis in patients with MDS compared with controls.
It is not known whether HbF is synthesized by the abnormal clonogenic cells of the MDS or whether it represents the ability of the bone marrow to reactivate fetal erythrocyte progenitors. 30 The higher proportion of F blasts in MDS than in stress erythropoiesis means that HbF production in MDS is beyond the level imposed by fetal erythropoietic drive during stress erythropoiesis. Furthermore, the HbF production was largely restricted to dysplastic erythroblasts or immature erythroid precursors, forming clusters or sheets of F blasts. Craig et al 21 demonstrated that HbF production was significantly higher in MDS patients with an abnormal karyotype than in those with a normal karyotype. Koc et al 31 found that the increased transcription of the alpha and gamma genes were partly responsible for the elevation of HbF in MDS. These results suggest that fetal-type erythropoiesis is associated with the abnormal clonogenic cells in MDS. However, Reinhardt et al 7 reported that there is no association between increased HbF production and karyotype abnormalities in patients with MDS. Analysis at the single-cell level in patients with positive cytogenetic markers of the clonogenic cells will be needed to resolve this issue.
In conclusion, a high apoptosis rate occurs in MDS patients with an elevated Fb/Fc ratio, suggesting that a considerable number of F blasts fail to mature into functioning end-stage F cells, despite vigorous F blast production in the bone marrow. The present study emphasizes the need to measure F blasts in the bone marrow rather than the number of F cells or the HbF concentrations for a more precise evaluation of fetal-type erythropoiesis in MDS.
